Great Point Partners Cut Sage Therapeutics (SAGE) Position By $4.44 Million; Barclays Plc Has Trimmed By $22.12 Million Its Banco Santander Sa (SAN) Position

October 13, 2017 - By Winifred Garcia

Barclays Plc decreased Banco Santander Sa (SAN) stake by 95.16% reported in 2017Q2 SEC filing. Barclays Plc sold 3.69M shares as Banco Santander Sa (SAN)’s stock rose 20.33%. The Barclays Plc holds 187,526 shares with $1.25M value, down from 3.87M last quarter. Banco Santander Sa now has $106.27B valuation. The stock declined 0.83% or $0.05 reaching $6.59 per share. About 107,832 shares traded. Banco Santander, S.A. (ADR) (NYSE:SAN) has risen 44.48% since October 13, 2016 and is uptrending. It has outperformed by 27.78% the S&P500.

Great Point Partners Llc decreased Sage Therapeutics Inc (SAGE) stake by 18.73% reported in 2017Q2 SEC filing. Great Point Partners Llc sold 56,200 shares as Sage Therapeutics Inc (SAGE)’s stock rose 0.86%. The Great Point Partners Llc holds 243,800 shares with $19.42M value, down from 300,000 last quarter. Sage Therapeutics Inc now has $2.31 billion valuation. The stock declined 0.52% or $0.33 reaching $61.74 per share. About shares traded. SAGE Therapeutics Inc (NASDAQ:SAGE) has risen 116.45% since October 13, 2016 and is uptrending. It has outperformed by 99.75% the S&P500.

Among 11 analysts covering Banco Santander (NYSE:SAN), 6 have Buy rating, 1 Sell and 4 Hold. Therefore 55% are positive. Banco Santander had 17 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Banco Santander, S.A. (ADR) (NYSE:SAN) has “Hold” rating given on Friday, July 31 by Kepler Cheuvreux. JP Morgan downgraded the stock to “Neutral” rating in Wednesday, September 30 report. BNP Paribas downgraded the shares of SAN in report on Thursday, February 9 to “Underperform” rating. The stock of Banco Santander, S.A. (ADR) (NYSE:SAN) has “Outperform” rating given on Monday, January 11 by BNP Paribas. The stock has “Buy” rating by Natixis on Tuesday, October 11. Barclays Capital upgraded Banco Santander, S.A. (ADR) (NYSE:SAN) on Tuesday, September 6 to “Overweight” rating. The rating was upgraded by Deutsche Bank to “Hold” on Friday, August 28. The firm has “Market Perform” rating by Wood given on Friday, April 28. The firm has “Buy” rating by JP Morgan given on Friday, April 21. The firm earned “Conviction Buy” rating on Tuesday, March 8 by Goldman Sachs.

Barclays Plc increased Esterline Technologies Corp (NYSE:ESL) stake by 30,073 shares to 39,272 valued at $3.72M in 2017Q2. It also upped Global Blood Therapeutics In stake by 55,476 shares and now owns 93,776 shares. Mcdonalds Corp (Call) (NYSE:MCD) was raised too.

Analysts await SAGE Therapeutics Inc (NASDAQ:SAGE) to report earnings on November, 2. They expect $-1.91 EPS, down 66.09% or $0.76 from last year’s $-1.15 per share. After $-1.88 actual EPS reported by SAGE Therapeutics Inc for the previous quarter, Wall Street now forecasts 1.60% negative EPS growth.

Among 15 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 12 have Buy rating, 0 Sell and 3 Hold. Therefore 80% are positive. SAGE Therapeutics had 32 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was initiated by Raymond James on Tuesday, September 13 with “Outperform”. The stock has “Outperform” rating by BMO Capital Markets on Thursday, September 14. H.C. Wainwright downgraded the shares of SAGE in report on Wednesday, February 22 to “Neutral” rating. The stock has “Strong Buy” rating by Raymond James on Wednesday, December 14. As per Thursday, August 3, the company rating was maintained by BMO Capital Markets. The firm has “Buy” rating by Needham given on Tuesday, June 13. Leerink Swann maintained the stock with “Buy” rating in Tuesday, September 12 report. The firm has “Sell” rating given on Tuesday, May 24 by Chardan Capital Markets. The rating was maintained by H.C. Wainwright with “Hold” on Friday, August 4. The rating was maintained by JP Morgan on Thursday, September 3 with “Buy”.

Investors sentiment decreased to 0.98 in 2017 Q2. Its down 0.13, from 1.11 in 2017Q1. It turned negative, as 24 investors sold SAGE shares while 61 reduced holdings. 30 funds opened positions while 53 raised stakes. 37.20 million shares or 2.18% more from 36.41 million shares in 2017Q1 were reported. One Trading Limited Partnership invested in 7,412 shares or 0.01% of the stock. Tekla Capital Management Limited Liability Corporation holds 0.27% or 90,480 shares. Envestnet Asset Mgmt reported 0% stake. 3,058 were reported by Cubist Systematic Strategies Limited Liability. Canada Pension Plan Inv Board owns 0% invested in SAGE Therapeutics Inc (NASDAQ:SAGE) for 2,200 shares. Brown Advisory, Maryland-based fund reported 3,111 shares. Thompson Davis & Communications accumulated 198 shares. Alyeska Inv Gru Lp reported 84,449 shares stake. Northwestern Mutual Wealth Mgmt Communication reported 34 shares. Artal Group Inc Sa has 90,000 shares for 0.13% of their portfolio. Moreover, Jefferies Grp Inc Lc has 0.01% invested in SAGE Therapeutics Inc (NASDAQ:SAGE) for 14,000 shares. Picton Mahoney Asset Mgmt stated it has 0.54% of its portfolio in SAGE Therapeutics Inc (NASDAQ:SAGE). Balyasny Asset Limited Liability Corp holds 0.06% or 190,500 shares in its portfolio. 20,334 are held by Suffolk Limited. Driehaus Limited Liability Corporation accumulated 0.03% or 11,139 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

>